You are adding an alert for:
INTRAVITREAL BEVACIZUMAB PLUS BRINZOLAMIDE VERSUS INTRAVITREAL BEVACIZUMAB FOR TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY: PILOT STUDY.
You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
The alert will be sent to: